Charles Schwab Investment Management Inc. Grows Stock Position in Codexis, Inc. (NASDAQ:CDXS)

Charles Schwab Investment Management Inc. boosted its position in shares of Codexis, Inc. (NASDAQ:CDXS) by 12.2% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 239,720 shares of the biotechnology company’s stock after buying an additional 26,052 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Codexis were worth $1,143,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Intech Investment Management LLC bought a new stake in shares of Codexis in the 3rd quarter worth about $66,000. Kingswood Wealth Advisors LLC purchased a new stake in Codexis in the 4th quarter worth about $79,000. China Universal Asset Management Co. Ltd. bought a new stake in Codexis in the fourth quarter worth about $82,000. Jackson Square Capital LLC bought a new stake in Codexis in the fourth quarter worth about $210,000. Finally, Inspire Investing LLC purchased a new position in shares of Codexis during the fourth quarter valued at approximately $405,000. Institutional investors own 78.54% of the company’s stock.

Codexis Price Performance

CDXS opened at $2.81 on Monday. The business has a fifty day moving average of $3.71 and a 200 day moving average of $3.95. The stock has a market cap of $232.77 million, a P/E ratio of -3.23 and a beta of 2.12. The company has a quick ratio of 3.15, a current ratio of 3.21 and a debt-to-equity ratio of 0.39. Codexis, Inc. has a 52-week low of $2.43 and a 52-week high of $6.08.

Codexis (NASDAQ:CDXS) last issued its earnings results on Thursday, February 27th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.09). Codexis had a negative return on equity of 71.56% and a negative net margin of 96.35%. The firm had revenue of $21.46 million during the quarter, compared to analysts’ expectations of $27.41 million. As a group, sell-side analysts anticipate that Codexis, Inc. will post -0.77 EPS for the current year.

About Codexis

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.